StartAPN • JSE
add
Aspen Pharmacare Holdings Ltd
Seneste lukkekurs
16.953,00 ZAC
Dagsinterval
16.800,00 ZAC - 17.048,00 ZAC
Årsinterval
16.310,00 ZAC - 25.296,00 ZAC
Markedsværdi
75,47 mia. ZAR
Gns. volumen
1,38 mio.
P/E-værdi
17,06
Udbytteprocent
2,12 %
Primær børs
JSE
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(ZAR) | jun. 2024info | År til år-ændring |
---|---|---|
Indtægt | 11,78 mia. | 9,30 % |
Driftsudgifter | 2,36 mia. | -3,24 % |
Nettoindtægt | 1,04 mia. | -18,17 % |
Overskudsgrad | 8,87 | -25,15 % |
Earnings per share | — | — |
EBITDA | 2,93 mia. | 7,80 % |
Effektiv afgiftssats | 25,52 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(ZAR) | jun. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 12,34 mia. | 13,06 % |
Samlede aktiver | 139,16 mia. | 3,63 % |
Samlede passiver | 54,29 mia. | 13,00 % |
Samlet egenkapital | 84,86 mia. | — |
Shares outstanding | 444,21 mio. | — |
Kurs/indre værdi | 0,89 | — |
Afkast af aktiver | 4,84 % | — |
Afkast af kapital | 5,56 % | — |
Pengestrøm
Nettoændring i likviditet
(ZAR) | jun. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 1,04 mia. | -18,17 % |
Pengestrøm fra drift | 1,88 mia. | -1,21 % |
Pengestrøm fra investering | -1,65 mia. | -79,92 % |
Pengestrøm fra finansiering | -141,50 mio. | 52,91 % |
Nettoændring i likviditet | -200,00 mio. | -118,37 % |
Fri pengestrøm | 525,31 mio. | -32,86 % |
Om
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
Administrerende direktør
Grundlagt
1850
Hovedkvarter
Website
Ansatte
9.109